Cryptogenic Cirrhosis: Causes, Diagnosis, and Treatment in the MASLD Era

What “cryptogenic” means

Cryptogenic cirrhosis is a working diagnosis, not a single disease. “Cirrhosis” describes advanced architectural scarring and regenerative nodules. “Cryptogenic” says that the cause has not been established with enough confidence after evaluation.

The label can change. Old records may reveal years of steatosis, heavy alcohol exposure, a medication injury, viral hepatitis, or abnormal autoimmune tests. New genetic or antibody testing may identify a previously missed condition. Explant pathology after liver transplantation can also supply clues that a small needle biopsy did not capture.

Cryptogenic does not mean that nothing can be done until a cause is found. Once cirrhosis is present, the risks of portal hypertension, decompensation, liver cancer, malnutrition, kidney injury, infection, and medication toxicity require active care regardless of etiology.

Why burned-out MASH is often considered

Metabolic dysfunction-associated steatotic liver disease, or MASLD, replaced the older NAFLD term in the 2023 multisociety nomenclature [2]. MASH is the inflammatory form associated with hepatocyte injury and a greater risk of progressive fibrosis. The diagnostic terminology now also distinguishes MASLD from alcohol-related disease and MetALD, in which metabolic dysfunction and higher alcohol exposure coexist.

In advanced MASH, the fat, ballooning, and inflammation that made the earlier disease recognizable can become less prominent. A cirrhotic liver may therefore look nonspecific. Older clinicopathologic studies found that people labeled with cryptogenic cirrhosis often shared diabetes, obesity, and other metabolic features with people who had known steatohepatitis [1]. This gave rise to the useful concept of “burned-out MASH.”

It remains an inference. Diabetes or obesity is common and can coexist with another liver disease. Conversely, MASLD can occur in a person without obesity. A strong attribution considers the full timeline: prior imaging, earlier liver enzymes, weight history, diabetes duration, alcohol exposure, medications, family history, and the completeness of the exclusion workup.

Confirming that cirrhosis is present

Cirrhosis may be recognized through nodular liver morphology, splenomegaly, collateral veins, low platelets, ascites, varices, elastography, or histology. A biopsy is not required in every case. The AASLD MASLD guidance allows cirrhosis-based management to begin when noninvasive tests, imaging, and clinical data strongly support the diagnosis [3].

Elastography estimates liver stiffness, but congestion, active inflammation, cholestasis, a recent meal, and technical factors can affect results. Blood-based scores such as FIB-4 are designed mainly to identify who needs secondary fibrosis assessment. Once a person already has clinical cirrhosis, repeating FIB-4 does not identify the original cause or replace evaluation for portal hypertension and complications.

The EASL noninvasive-test guideline supports sequential use of simple blood tests and elastography in at-risk populations [4]. Cutoffs differ by setting, age, device, and purpose. A single universal stiffness threshold should not be used to reclassify every cryptogenic case as MASH.

Building the cause-of-cirrhosis workup

The evaluation is tailored to age, ancestry, exposures, laboratory pattern, and prior records. A typical review includes:

• hepatitis B and C testing, with confirmatory nucleic-acid testing when indicated;
• a careful lifetime alcohol history, including changes after illness began;
• prescription, over-the-counter, supplement, and occupational exposures;
• antinuclear, smooth-muscle, and antimitochondrial antibodies plus immunoglobulins when autoimmune or cholestatic disease is plausible;
• iron indices and targeted HFE testing when iron overload is suspected;
• alpha-1 antitrypsin level and phenotype or genotype when appropriate;
• ceruloplasmin and additional copper evaluation in the right age and clinical setting;
• imaging of bile ducts and hepatic or portal vasculature when the pattern suggests obstruction or vascular disease;
• selected evaluation for celiac disease, cardiac congestion, rare genetic disease, or other causes based on the presentation.

Not every test belongs in every patient. For example, a positive autoantibody at low titer can be nonspecific, while normal aminotransferases do not exclude advanced liver disease. The goal is an integrated explanation, not a checklist interpreted without context.

What historical records can add

Prior ultrasound, CT, or MRI showing steatosis before cirrhosis is useful evidence for a metabolic pathway. Earlier biopsy slides can be rereviewed by an expert liver pathologist. Longitudinal weight, A1c, triglycerides, and liver enzymes can show whether metabolic disease preceded scarring.

A liver biopsy can still help when diagnosis would change treatment, but advanced cirrhosis is heterogeneous and sampling is limited. Bleeding risk, ascites, and whether a transjugular approach is needed also matter. Biopsy should answer a defined question, not be ordered merely because the label says cryptogenic.

Staging risk after the diagnosis

The most important distinction is often compensated versus decompensated cirrhosis. Compensated disease has not produced ascites, variceal bleeding, or overt hepatic encephalopathy. Decompensation marks a major change in prognosis and usually increases the urgency of transplant evaluation.

In a prospective cohort of 1,773 adults across the MASLD fibrosis spectrum, stage F4 disease was associated with higher rates of death and liver-related complications than F0-F2 disease. Development of ascites, variceal hemorrhage, or encephalopathy was strongly associated with mortality [5]. This is why surveillance and prevention continue even when a person feels well.

Common risk measures include MELD 3.0 or MELD-Na, Child-Pugh class, albumin, bilirubin, INR, creatinine, sodium, platelet count, and the history of complications. No score replaces clinical judgment. Recurrent hospitalizations, frailty, falling albumin, or kidney dysfunction can be important even before a numerical threshold is crossed.

Portal hypertension and varices

Scarred liver tissue increases resistance to portal blood flow. Consequences include splenomegaly, thrombocytopenia, collateral veins, varices, ascites, and portal-hypertensive gastropathy. The Baveno VII consensus uses noninvasive criteria in selected compensated patients to estimate clinically significant portal hypertension and determine who can avoid or needs endoscopy [6].

The plan can involve liver stiffness, platelet count, imaging, and upper endoscopy. Nonselective beta blockers may lower the risk of decompensation or bleeding in appropriately selected patients with clinically significant portal hypertension. Choice and titration depend on blood pressure, kidney function, ascites, heart rate, and comorbidities; a fixed online regimen is not safe for every patient.

Vomiting blood, black stools, fainting, or sudden weakness can signal gastrointestinal bleeding and requires emergency evaluation.

Liver-cancer surveillance

Cirrhosis from MASH or an uncertain cause carries hepatocellular carcinoma risk. The 2023 AASLD HCC guidance recommends surveillance with ultrasound and AFP approximately every six months for eligible patients with cirrhosis [7]. Surveillance is intended for people who could benefit from treatment if a cancer is found.

Ultrasound quality can be limited by obesity, liver heterogeneity, or anatomy. The report should document visualization quality. When ultrasound is repeatedly inadequate, contrast-enhanced MRI or multiphase CT may be considered for surveillance based on specialist judgment [7]. An abnormal AFP or lesion does not establish cancer by itself; it triggers diagnostic imaging and an appropriate pathway.

Ascites, infection, kidney injury, and encephalopathy

New ascites should be evaluated rather than assumed to be simple fluid retention. Diagnostic paracentesis helps determine portal-hypertension physiology and checks for infection when appropriate. Diuretics, sodium strategy, large-volume paracentesis with albumin, and other treatment depend on the clinical setting and kidney function [8].

Fever, abdominal pain, confusion, falling blood pressure, worsening kidney function, or hospitalization in a person with ascites should raise concern for infection, including spontaneous bacterial peritonitis. Antibiotic prophylaxis is reserved for defined high-risk situations; it is not a blanket treatment for everyone with ascites.

Overt hepatic encephalopathy can be precipitated by infection, bleeding, constipation, dehydration, kidney problems, sedating medicines, or electrolyte disturbance. Treatment addresses the trigger and uses therapies such as lactulose and, for selected recurrence prevention, rifaximin. New confusion or marked sleepiness needs prompt assessment because not every mental-status change in cirrhosis is encephalopathy.

Nutrition, muscle, and safe weight management

Metabolic disease management remains important, but aggressive weight loss can be harmful once cirrhosis and sarcopenia are present. Muscle loss worsens frailty and outcomes. The AASLD nutrition guidance recommends screening people with cirrhosis for malnutrition, frailty, and sarcopenia and individualizing energy, protein, meal timing, and physical activity [9].

Earlier-stage MASH studies show a dose-response relationship between weight loss and histologic improvement [14]. Those results should not be copied into an unsupervised crash diet for a patient with F4 cirrhosis. A person with compensated cirrhosis, obesity, and preserved muscle may benefit from gradual fat loss paired with adequate protein and resistance activity. Someone with decompensation, unintentional weight loss, or muscle wasting may need a different priority: restoring intake and function.

Cardiovascular risk, diabetes, lipids, sleep apnea, and physical activity deserve treatment because cardiovascular disease remains a major competing risk in MASLD. Medication selection must account for liver function, kidney function, hypoglycemia risk, and nutritional status.

What the MASH drug approvals do and do not mean

Resmetirom

In MAESTRO-NASH, resmetirom improved MASH resolution and fibrosis endpoints compared with placebo in adults with biopsy-confirmed noncirrhotic NASH and F1B-F3 fibrosis [10]. The FDA approved resmetirom in 2024 for adults with noncirrhotic MASH/NASH and moderate-to-advanced fibrosis consistent with F2-F3, alongside diet and exercise [11].

That indication does not include established F4 cirrhosis. The label advises avoiding resmetirom in decompensated cirrhosis. A cryptogenic-cirrhosis diagnosis should therefore not be converted into a resmetirom prescription merely because burned-out MASH is suspected.

Semaglutide

The ESSENCE phase 3 interim analysis studied adults with MASH and F2-F3 fibrosis. At 72 weeks, semaglutide improved both MASH-resolution and fibrosis endpoints compared with placebo [12]. The FDA granted accelerated approval in August 2025 for the Wegovy formulation to treat adults with noncirrhotic MASH and F2-F3 fibrosis [13].

Again, the MASH indication is noncirrhotic. Semaglutide may have a separate approved indication in a person with obesity, overweight plus a qualifying condition, cardiovascular disease, or diabetes treatment needs, but established cirrhosis changes the risk-benefit and monitoring discussion. Loss of appetite, vomiting, dehydration, gallbladder disease, and excessive lean-mass loss can be especially consequential in vulnerable cirrhosis.

Avoiding category errors

Histologic improvement in F2-F3 disease is not proof that a drug reverses portal hypertension, prevents decompensation, or improves survival in cryptogenic F4 cirrhosis. Drug trials, labels, and clinical outcomes must match the actual stage. This boundary is both medically important and easy to lose when a page combines “MASH fibrosis” and “cirrhosis” as though they were interchangeable.

A practical care pathway

1. Verify the diagnosis and stage. Assemble imaging, laboratory trends, prior pathology, and signs of portal hypertension. Determine whether disease is compensated or decompensated.

2. Reconstruct the etiology. Evaluate viral, alcohol-related, autoimmune, cholestatic, inherited, vascular, drug-related, and metabolic explanations. Record the completeness and limitations of the workup.

3. Treat the person as having cirrhosis now. Set HCC surveillance, portal-hypertension assessment, vaccination review, medication review, and monitoring for kidney and nutritional risk without waiting for perfect etiologic certainty.

4. Manage metabolic risk without sacrificing muscle. Address diabetes, lipids, cardiovascular risk, diet quality, and activity. Screen for frailty and use a dietitian or physical therapist when weight loss or exercise could be unsafe.

5. Match therapies to stage and indication. Do not apply an F2-F3 MASH drug approval to F4 cirrhosis. Treat specific cirrhosis complications according to current hepatology guidance.

6. Reassess transplant timing. Ascites, variceal bleeding, encephalopathy, liver cancer, worsening MELD, kidney dysfunction, or repeated hospitalization should prompt timely transplant-center discussion when appropriate.

Transplant evaluation and recurrence risk

Liver transplantation is considered for decompensated cirrhosis, selected liver cancers, or other high-risk trajectories. Referral is not the same as listing. Early evaluation allows time to assess cardiovascular disease, frailty, nutrition, social support, substance use, and potential barriers before an emergency develops.

If the original disease was MASH, the transplanted liver remains exposed to the recipient's metabolic environment. Weight gain, diabetes, dyslipidemia, and immunosuppressive effects can lead to recurrent steatosis. Post-transplant care therefore includes cardiovascular and metabolic risk management, but immunosuppression changes belong to the transplant team rather than a generic metabolic protocol.

When to seek urgent care

Urgent assessment is appropriate for vomiting blood, black stools, new or rapidly worsening abdominal swelling, fever with ascites, new confusion, severe sleepiness, jaundice that is worsening, reduced urine, fainting, difficulty breathing, or severe weakness. These can signal bleeding, infection, kidney injury, encephalopathy, or another decompensation event.